Yüklüyor......
Prolonged survival after bevacizumab rechallenge in glioblastoma patients with previous response to bevacizumab(†)
BACKGROUND. The use of bevacizumab for recurrent glioblastoma is controversial. Here we show data on patients who responded to bevacizumab, then stopped bevacizumab for any reason other than progression and were rechallenged with bevacizumab at the time of subsequent progression. METHODS. This retro...
Kaydedildi:
| Yayımlandı: | Neurooncol Pract |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Oxford University Press
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6655406/ https://ncbi.nlm.nih.gov/pubmed/31385992 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/nop/npw004 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|